antisense drugs Archives -

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase

Pfizer sees no way forward for Ionis-partnered vupanorsen

https://pharmaphorum.com/news/pfizer-sees-no-way-forward-for-ionis-partnered-vupanorsen/

Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed

Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?

https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/

Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra

NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use

https://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a

Ionis deal delivers for GSK as HBV drug hits the mark in phase 2

https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/

Ionis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in

Roche takes on development of potential Huntington’s breakthrough

https://pharmaphorum.com/news/roche-takes-development-potential-huntingtons-breakthrough/

antisense drugs